[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"transcatheter-aortic-valve-replacement\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:transcatheter-aortic-valve-replacement":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,45,71,94,126,151,175,193,214,242,264,286,315,337,369,394],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100497550","phase-4-ct-tavr-abdomen-study-100497550",false,"NCT05758701","CT TAVR Abdomen Study","Dual Energy CT Decreased IV Contrast Dose Imaging for TAVR","CT TAVR","Inclusion Criteria:\n\n* scheduled to receive TAVR abdominal CT\n\nExclusion Criteria:\n\n* cannot undergo CT scan\n* Allergy to intravenous contrast not controlled by steroids or benadryl\n* GFR\\\u003C30",true,"ALL","18 Years","88 Years",{"count":22,"type":23},164,"ESTIMATED","INTERVENTIONAL",[26],"PHASE4","A standard polyenergetic CT (computed tomography) procedure utilizes 100 ml of iodinated contrast. A recent world-wide shortage of iodine based intravenous contrast has highlighted the need to search for alternative methods or doses. Reducing iodinated IV contrast dose can mitigate IV contrast supply shortages and enable significant cost savings for the radiology practice and hospital system. In addition, decreased IV contrast dose can potentially reduce the rate of acute kidney injury, specifically in patients with decreased renal function. The purpose of the study is to determine whether low IV contrast dose CT with monoenergetic reconstruction can be use for presurgical planning of transcatheter valve replacement (TAVR) procedure.",[29],"Transcatheter Aortic Valve Replacement",[31],"Dual energy CT","RECRUITING","2026-06-29",{"date":35,"type":36},"2026-07-01","ACTUAL",{"date":38,"type":36},"2023-09-19",{"date":40,"type":23},"2028-03-01",{"name":42,"class":43},"University of Maryland, Baltimore","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":24,"phases":54,"briefSummary":56,"conditions":57,"keywords":58,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":44},"100583088","comparison-of-single-vs-dual-perclose-devices-for-large-bore-access-closure-in-tavr-100583088","NCT06871774","Comparison of Single vs. Dual Perclose Devices for Large-Bore Access Closure in TAVR","Comparative Efficacy of Single vs. Dual Perclose Devices for Large-Bore Access Closure in Transcatheter Aortic Valve Replacement: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Patient age 18 or older\n* Transfemoral transcatheter aortic valve replacement (TAVR)\n* Implantation of CoreValve replacement valve\n* Access using 14 French sheaths\n* English speaking\n\nExclusion Criteria:\n\n* Alternative Access Routes: Patients undergoing transcatheter aortic valve replacement (TAVR) via alternative access routes such as subclavian access or transapical access.\n* Planned Surgical Cut-Down: Patients planned for surgical cut-down procedures rather than percutaneous access.\n* Vascular Access Complications: Patients with known vascular complications at the femoral access site, such as residual hematoma, recent femoral arteriotomy or venotomy within the past 10 days, history of significant vascular complications or prior intravascular closure device use within the previous 30 days.\n* Arterial or Venous Issues: Patients with small femoral arteries or veins (\\\u003C5 mm in diameter), patients with access sites located in vascular grafts.\n* Body Composition: Patients with BMI \\>35\n* Cardiac Vasculature: Patients with excess calcification of vessels as determined by echocardiography and\u002For CT angiography\n* Infection or Inflammation: Active systemic or cutaneous infection or inflammation in the vicinity of the groin.\n* Coagulation and Hematological Disorders: Known history of bleeding diathesis, coagulopathy, hypercoagulability, or platelet count \\\u003C100,000 cells\u002Fmm³. Pre-existing immunodeficiency disorder or chronic use of high-dose systemic steroids.\n* Severe Morbidity: Severe co-existing morbidities with a life expectancy less than 12 months.\n* Mobility Issues: Patients unable to routinely walk at least 20 feet without assistance.\n* Recent Anticoagulation: Use of low molecular weight heparin (LMWH) within 8 hours before or after the procedure.\n* Pregnancy and Lactation: Pregnant or lactating women.\n* Incompatible Procedure Plan: Patients receiving the Edwards Sapien valve (Edwards Lifesciences, Irvine, CA)\n* Contraindications: Patients with contraindications for the use of Perclose device.",{"count":53,"type":23},300,[55],"NA","This study will compare the use of one Perclose device to the usual approach of two devices for pre-closure during Transcatheter Aortic Valve Replacement (TAVR). The study will compare the time it takes for bleeding to stop using the different closure approaches. The study will also compare complications when using one Perclose device versus two.",[29],[59,60,61],"aortic valve diseases","Perclose device","arteriotomy","2026-06-24",{"date":64,"type":36},"2026-06-25",{"date":66,"type":36},"2025-06-16",{"date":68,"type":23},"2027-06",{"name":70,"class":43},"Wake Forest University Health Sciences",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":44},"100621426","transcatheter-mitral-and-tricuspid-interventions-a-cardiac-magnetic-resonance-study-100621426","NCT07370467","Transcatheter Mitral and Tricuspid Interventions: a Cardiac Magnetic Resonance Study","TEMATIC-MR: Transcatheter Mitral and Tricuspid Interventions: a Cardiac Magnetic Resonance Study","TEMATIC-MR","Inclusion Criteria:\n\n* Age ≥ 18 anni\n* Signing informed consent\n* Patients who are candidates for transcatheter mitral or tricuspid surgery (TEER, TTVR).\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Contraindications to CMR or administration of contrast medium (gadolinium)",{"count":80,"type":23},250,"OBSERVATIONAL","Mitral and tricuspid valve disease represents an increasing challenge in the management of patients with heart failure and other cardiovascular diseases. In recent years, the introduction of transcatheter techniques for valve repair and replacement (TVI) has revolutionised the treatment of these diseases, particularly for patients at high surgical risk or who are not candidates for traditional surgery. However, although these procedures are increasingly popular, their long-term effectiveness in terms of cardiac remodelling is still not well understood.\n\nCardiac magnetic resonance (CMR) techniques, with their advanced capabilities to provide anatomical and functional details of the heart, offer a unique opportunity to assess ventricular remodelling and valve function before and after transcatheter interventions. The ESC guidelines on valvulopathies published in 2021 recommend the use of cardiac magnetic resonance imaging not only to quantify the extent of mitral and tricuspid regurgitation when echocardiography is inconclusive, but also as the gold standard for the assessment of left and right ventricular size and function (limited, however, to the availability of this method in the various centres). Currently, there are few systematic data evaluating the effect of these procedures on CMR-assessed cardiac anatomy and function. This study aims to fill this gap by creating a multicentre registry in which clinical and advanced imaging data, including 3D echocardiography and CMR, are collected to assess the impact of these therapies.\n\nAnalysis of data derived from advanced imaging will not only provide a better understanding of the mechanism of operation of transcatheter techniques, but will also provide important information for improving long-term patient outcomes by identifying potential predictors of treatment success or failure.",[84,29],"Mitral Insufficiency","2026-06-08",{"date":87,"type":36},"2026-06-09",{"date":89,"type":36},"2026-01-30",{"date":91,"type":23},"2026-09-30",{"name":93,"class":43},"Centro Cardiologico Monzino",{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":102,"targetDuration":104,"studyType":81,"phases":4,"briefSummary":105,"conditions":106,"keywords":109,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":44},"100373222","prospective-validation-of-a-pre-specified-algorithm-for-the-management-of-conduction-disturbances-following-tavr-100373222","NCT04139616","Prospective Validation of a Pre-Specified Algorithm for the Management of Conduction Disturbances Following TAVR","Prospective Validation of a Pre-Specified Algorithm for the Management of Conduction Disturbances Following Transcatheter Aortic Valve Replacement. The PROMOTE Study","PROMOTE","Inclusion Criteria:\n\n-Patients with aortic valve disease undergoing transcatheter aortic valve replacement\n\nExclusion Criteria:\n\n* Prior permanent pacemaker\n* Failure to provide signed informed consent for data collection\n* Impossibility for a follow-up\n* Unwillingness to follow the pre-specified strategy for the management of conduction disturbances",{"count":103,"type":23},2000,"1 Year","The high incidence and variety of conduction disturbances post-TAVR represents a major challenge in the periprocedural management of TAVR recipients. Despite the growing body of knowledge on this topic, the large variability in the management of these complications has translated into a high degree of uncertainty regarding the most appropriate treatment of a large proportion of such patients. The implementation of a pre-specified treatment strategy translating into a more uniform practice regarding the management of conduction disturbances post-TAVR applied to a large cohort of patients would permit to identify the benefits and drawbacks of each specific aspect of the treatment algorithm proposal. This may also help to improve both the management and clinical outcomes of the complex group of patients with conduction disturbances associated with TAVR. In the end, the final objective of a pre-specified strategy for managing conduction disturbances post-TAVR should be to obtain a low rate of PPM without increasing the risk of sudden death or life threatening arrhythmic events following hospital discharge, and all this while avoiding an excessive prolongation of the hospitalization period following the TAVR procedure.",[107,29,108],"Conduction Disturbances","Permanent Pacemaker Implantation",[110,111,112,113,114,115,116],"atrioventricular block","complete heart block","high-degree atrioventricular block","intraventricular conduction delay","left bundle branch block","Permanent pacemaker implantation","Right bundle branch block","2026-05-28",{"date":119,"type":36},"2026-06-01",{"date":121,"type":36},"2020-02-25",{"date":123,"type":23},"2027-12-25",{"name":125,"class":43},"Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":18,"minAge":134,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":24,"phases":137,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":44},"100559069","coronary-artery-disease-assessment-strategies-in-tavi-patients-100559069","NCT06559332","Coronary Artery Disease Assessment Strategies in TAVI Patients","Randomized Trial of Coronary Artery Disease Assessment Strategies in Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation","CAT","Inclusion:\n\n• Severe aortic stenosis defined by aortic valve area (AVA) ≤1cm2 AND mean gradient ≥40 mmHg or peak velocity ≥4.0 m\u002Fs\n\nOR\n\nif mean gradient \\\u003C40 mmHg and peak velocity (Vmax) \\\u003C4 m\u002Fs and stroke volume indexed to body surface area (SVi) ≤ 35 mL\u002Fm2 and LVEF ≥50% then if CT-derived aortic valve calcium score \\>2000 Agatston units in men, \\>1200 in women\n\nOR\n\nif mean gradient \\\u003C40 mmHg and Vmax \\\u003C4 m\u002Fs and SVi ≤ 35 mL\u002Fm2 and LVEF \\\u003C50% then if CT-derived aortic valve calcification \\>2000 Agatston units in men, \\>1200 in women OR if low-dose dobutamine stress echocardiography with flow reserve (\\>20% increase in stroke volume) and AVA ≤1cm2\n\n* Coronary calcium score ≥ 400 Agatston units (derived from routine pre-TAVI CT) or known coronary artery disease\n* Selected for treatment with transfemoral TAVI.\n* Written informed consent.\n\nExclusion Criteria:\n\n* Concomitant valvular heart disease or ascending aortic aneurysm with indication for surgery or intervention\n* Unprotected left main coronary stenosis \\>50% or left main not evaluable based on coronary computed tomography angiography derived from routine pre-TAVI CT\n* Left ventricular ejection fraction (LVEF) \\\u003C 30%\n* New regional wall motion abnormalities on echocardiography\n* Myocardial infarction in previous 12 months\n* Coronary angiography in previous 12 months\n* Prior left main stenting","70 Years",{"count":136,"type":23},546,[55],"Coronary artery disease (CAD) and aortic stenosis frequently coincide. Before valve intervention, invasive coronary angiography is routinely performed to assess coronary status.\n\nAs the impact of percutaneous revascularization on clinical outcomes beyond symptom improvement is subject to debate and treatment of aortic stenosis itself reduces ischemic burden and symptoms, the benefit\u002Frisk balance of routine invasive coronary angiography prior to transcatheter aortic valve implantation (TAVI) is unclear.\n\nThe CAT Trial aims to compare a non-invasive risk management strategy to routine invasive coronary angiography for the assessment of coronary artery disease in patients with severe, symptomatic aortic stenosis selected to undergo TAVI with respect to adverse clinical outcomes at 3 years (primary objective) and patient reported outcome measures (secondary objective).",[29,140,141],"Coronary Artery Disease","Heart Disease Risk Factors","2026-05-07",{"date":144,"type":36},"2026-05-08",{"date":146,"type":36},"2025-03-11",{"date":148,"type":23},"2032-03-31",{"name":150,"class":43},"Insel Gruppe AG, University Hospital Bern",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":159,"targetDuration":161,"studyType":81,"phases":4,"briefSummary":162,"conditions":163,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":174},"100516163","ischemic-and-bleeding-risk-assessment-after-tavr-100516163","NCT06000943","Ischemic And Bleeding Risk Assessment After TAVR","Ischemic And Bleeding Risk Assessment After TAVR (FOCUS ONE Registry)","FOCUS ONE","Inclusion criteria\n\n* All patients with severe aortic stenosis undergoing TAVR.\n* Availability of changes in antithrombotic therapy at 1 month, 90 days, and 1 year after TAVR.\n\nExclusion Criteria\n\n* Patients who died during the index procedure\n* Patients in triple antithrombotic therapy at discharge\n* Patients with a known prognosis less than 1 year at the time of TAVR",{"count":160,"type":23},2500,"3 Years","Transcatheter aortic valve replacement (TAVR) represents an effective treatment to improve symptoms and prognosis in patients with symptomatic severe aortic stenosis (AS) (1-2).\n\nGiving an established uniform approach towards anticoagulation and antithrombotic therapy after TAVR in the post POPULAR-TAVI era, recent data coming from the analysis of different trials, highlight the relevance of the patient's background on the occurrence of ischemic and bleeding events.\n\nDespite this a targeted antithrombotic strategy remains unexplored and all patients undergoing TAVR without other indication to DAPT or OAC, were currently treated according with the concept of \"less is more\" (only SAPT or only OAC) regardless the risk level (5-6).\n\nThe keys points of the project will be 1) the assessment of ischemic and bleeding risk after TAVR stratified according with antithrombotic therapy and surgical risk; 2) the evaluation of the impact of prostheses type and the complete blood count variables (hemoglobine and platelets) on the daily average ischemic and bleeding risk and 3) the evaluation of the dynamic therapeutic changes after TAVR during the follow up.",[164,29],"Aortic Valve Stenosis","2026-04-13",{"date":167,"type":36},"2026-04-16",{"date":169,"type":36},"2023-08-01",{"date":171,"type":23},"2026-12-15",{"name":173,"class":43},"Niguarda Hospital",12,{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":181,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":183,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":185,"conditions":186,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":187,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":44},"100499171","coronary-re-engagement-after-random-navitor-alignment-comfort-study-100499171","NCT05779787","COronary Re-engageMent aFter randOm NavitoR alignmenT (COMFORT STUDY)","COronary Re-EngageMent aFter RandOm NavitoR Alignment (COMFORT STUDY)","COMFORT","Patients to be included in this registry should have all the following criteria:\n\n1\\. Severe, symptomatic aortic stenosis with an indication to TAVI\n\nExclusion criteria and definition\n\nPatients excluded in this registry should have all the following criteria:\n\n1. Valve in Valve procedure\n2. Hemodynamical instability\n3. TAVR performed from other access (not femoral)\n4. No-CT Planned TAVR\n5. TAVR performed with Chimney Technique",{"count":184,"type":23},100,"Whereas PCI before TAVR was previously recommended despite its uncertain prognostic role, recent data underline the possibility of a postponed coronary intervention using a commissural alignment technique. This approach allows easy coronary re-engagement through the valve stent frame with a trade off paid of procedure complexity.\n\nConsidering the prevalence of coronary artery disease (CAD) and the increasing percentage of younger patients treated with TAVI, investigate whether a simpler procedure with random implantation of Navitor valve is not inferior in terms of coronary re-access, is required The key point of the project will be the evaluation of the feasibility of coronary re-engagement after a Navitor valve randomly implanted.",[164,29],{"date":167,"type":36},{"date":189,"type":36},"2023-02-15",{"date":191,"type":23},"2027-05-15",{"name":173,"class":43},{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":200,"enrollmentInfo":201,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":203,"conditions":204,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":44},"100548425","valve-performance-of-the-sapien-3-ultra-resilia-valve-a-prospective-registry-with-central-echocardiography-analysis-100548425","NCT06420830","Valve Performance of the SAPIEN 3 Ultra RESILIA Valve: A Prospective Registry With Central Echocardiography Analysis.","Title Valve Performance of the SAPIEN 3 Ultra RESILIA Valve: A Prospective Registry With Central Echocardiography Analysis.","Inclusion Criteria:\n\n* Inclusion criteria - Patients with severe aortic stenosis undergoing transarterial TAVR with the SAPIEN 3 Ultra RESILIA valve.\n* Successful valve implantation of the SAPIEN 3 Ultra RESILIA valve.\n\nVARC-3- defined technical success defined as:\n\n* Freedom from mortality\n* Successful access, delivery of the device, and retrieval of the delivery system\n* Correct positioning of a single prosthetic heart valve into the proper anatomical location\n* Freedom from surgery or intervention related to the device (excluding permanent pacemaker) or to a major vascular or access related, or cardiac structural complication - Absence of severe procedural or in-hospital complications (VARC-3 definitions): mortality, stroke, bleeding type 2-4, myocardial infarction, need for a second valve, valve embolization, coronary obstruction, annular rupture.\n\nExclusion Criteria:\n\n* Age \\>80 years\n* Severe pulmonary disease (FEV1 \\\u003C50% predicted or need for home oxygen)\n* Severe renal dysfunction (eGFR \\\u003C30 ml\u002Fmin\u002F1.73m2)\n* Frailty (Clinical Frailty Scale \\> 4)\n* Severe coronary disease (SYNTAX score \\>32)\n* Left ventricular ejection fraction ≤30%\n* Moderate-to-severe mitral regurgitation\n* Severe tricuspid regurgitation\n* Pulmonary systolic pressure \\>60 mmHg\n* STS-PROM \\>5%\n* Any disease leading to a life expectancy \\\u003C5 years","80 Years",{"count":202,"type":23},150,"The issue of valve durability has become one of the most important aspects in the TAVR field in recent years since transcatheter aortic valve replacement has been progressively applied to younger patients with a low co-morbidity burden. The SAPIEN 3 Ultra RESILIA valve represents the last generation of the SAPIEN valve system and includes several important iterations (newer leaflet calcium-blocking technology targeting calcium-attracting free aldehydes, dry tissue storage, newer skirt textile design) that should translate into a favorable impact on valve durability at mid- to long- term follow-up",[164,29],"2026-03-23",{"date":207,"type":36},"2026-03-27",{"date":209,"type":36},"2024-05-16",{"date":211,"type":23},"2034-09-01",{"name":213,"class":43},"Institut universitaire de cardiologie et de pneumologie de Québec, University Laval",{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":220,"eligibilityCriteria":221,"healthyVolunteers":11,"sex":18,"minAge":222,"maxAge":223,"enrollmentInfo":224,"targetDuration":4,"studyType":24,"phases":226,"briefSummary":227,"conditions":228,"keywords":4,"overallStatus":231,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":44},"100624602","low-dose-colchicine-for-thromboprophylaxis-after-transcatheter-aortic-valve-replacement-100624602","NCT07411768","Low-dose Colchicine for Thromboprophylaxis After Transcatheter Aortic Valve Replacement","A Randomized Controlled Trial of Anti-Inflammatory Therapy to Reduce Transcatheter Heart Valve Thrombosis After Transfemoral Transcatheter Aortic Valve Replacement","LoDoCo-TAVR","Inclusion Criteria:\n\n* Patients with aortic stenosis aged 60-85 years.\n* Successful transfemoral TAVR (per VARC-3 criteria).\n* Voluntary participation with signed Informed Consent Form.\n\nExclusion Criteria:\n\n* Known hypersensitivity, allergy, or documented intolerance to colchicine.\n* Hematologic abnormalities defined as hemoglobin \\\u003C80 g\u002FL or white blood cell count \\\u003C4.0 × 10⁹\u002FL at screening.\n* Severe renal impairment defined as creatinine clearance \\\u003C30 mL\u002Fmin (calculated by the Cockcroft-Gault formula) or serum creatinine \\>2 × upper limit of normal (ULN).\n* Significant hepatic disease, including liver cirrhosis, chronic active hepatitis, hepatic injury (alanine aminotransferase \\>3 × ULN or total bilirubin \\>2 × ULN), or cholestasis.\n* Known history of bone marrow suppression.\n* Concomitant use of strong CYP3A4 or P-glycoprotein (P-gp) inhibitors, including but not limited to cyclosporine, amiodarone, clarithromycin, erythromycin, omeprazole, or verapamil.\n* Concomitant use of strong CYP3A4 or P-glycoprotein (P-gp) inducers, including but not limited to carbamazepine, phenobarbital, phenytoin, or rifampin.\n* Known neuromuscular disorders or creatine kinase (CK) \\>3 × ULN at screening.\n* Inflammatory bowel disease (Crohn's disease or ulcerative colitis) or chronic diarrhea.\n* Active malignancy or history of cancer.\n* Current use of systemic corticosteroids (oral or intravenous) or systemic immunosuppressive agents (topical or inhaled corticosteroids permitted).\n* Acute inflammatory condition or active viral infection at the time of enrollment.\n* Known galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.\n* Estimated life expectancy \\\u003C1 year as determined by the investigator.","60 Years","85 Years",{"count":225,"type":23},116,[55],"This prospective, randomized, open-label study aims to evaluate the efficacy and safety of low-dose colchicine (0.5 mg daily) in reducing transcatheter heart valve (THV) thrombosis in patients after TAVR. Participants will be randomly assigned to either receive colchicine plus standard care or standard care alone for 12 months. The primary goal is to compare the rate of valve thrombosis between the two groups using 4D-CT imaging at one year. Additionally, the study will evaluate the treatment's impact on clinical outcomes and its overall safety profile.",[29,229,230],"Transcatheter Heart Valve Thrombosis","Anti-inflammatory Therapy","NOT_YET_RECRUITING","2026-03-11",{"date":234,"type":36},"2026-03-12",{"date":236,"type":23},"2026-03",{"date":238,"type":23},"2028-06",{"name":240,"class":241},"China National Center for Cardiovascular Diseases","OTHER_GOV",{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":4,"eligibilityCriteria":248,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":249,"targetDuration":4,"studyType":24,"phases":251,"briefSummary":252,"conditions":253,"keywords":4,"overallStatus":231,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":44},"100627839","tavr-for-aortic-regurgitation-under-tee-guidance-100627839","NCT07453849","TAVR for Aortic Regurgitation Under TEE Guidance","Radiation- and Contrast-Free TAVR for Aortic Regurgitation Under Transesophageal Echocardiography Guidance","Inclusion Criteria:\n\n* Age ≥18 years.\n* Severe native aortic regurgitation (AR) confirmed by echocardiography (per guideline-recommended multiparametric assessment).\n* Indication for intervention, defined as symptomatic severe AR (e.g., NYHA class II-IV) or asymptomatic severe AR with evidence of LV decompensation (e.g., reduced LVEF and\u002For LV dilation per guideline thresholds).\n* Deemed appropriate for transfemoral TAVR by a multidisciplinary Heart Team (e.g., elevated\u002Fprohibitive surgical risk or other clinical\u002Fanatomic factors favoring transcatheter therapy).\n\nExclusion Criteria:\n\n* Active infective endocarditis or ongoing systemic infection\u002Fsepsis.\n* Aortic pathology requiring open surgery, such as significant ascending aortic aneurysm\u002Froot disease above surgical thresholds, acute aortic syndrome, or other conditions where surgery is mandated.\n* Annulus\u002Flanding-zone dimensions outside device range",{"count":250,"type":23},30,[55],"Under contemporary practice, transcatheter aortic valve replacement (TAVR) is typically performed with fluoroscopic visualization and repeated injections of iodinated contrast. While effective, this paradigm introduces cumulative radiation exposure to both patients and staff and can be problematic in individuals with renal dysfunction, prior contrast reactions, or other situations where contrast use is undesirable. Treating native aortic regurgitation (AR) adds another layer of complexity: limited valvular\u002Fannular calcification, enlarged annular dimensions, and dynamic root motion may reduce frictional \"purchase\" and make prosthesis stabilization more demanding, thereby heightening the need for continuous, high-fidelity intraprocedural imaging. Transesophageal echocardiography (TEE), with its close acoustic window to the aortic root, provides detailed real-time information on annular geometry, cusp coaptation, LVOT-aortic root alignment, guidewire trajectory, and implant depth, and it allows immediate confirmation of valve function and rapid recognition of adverse events (e.g., significant paravalvular regurgitation, maldeployment, pericardial effusion, or coronary compromise). Leveraging TEE as the dominant imaging modality therefore represents a pragmatic pathway toward a low-radiation and potentially contrast-sparing-or in selected cases, contrast-free-TAVR workflow. Nevertheless, evidence supporting an \"echo-only\" TEE-guided approach remains sparse, especially for native AR. In this study, we present a standardized TEE-guided procedural protocol and report feasibility and early clinical outcomes of TEE-only TAVR in patients with aortic regurgitation.",[254,29],"Aortic Regurgitation","2026-03-02",{"date":257,"type":36},"2026-03-06",{"date":259,"type":23},"2026-03-01",{"date":261,"type":23},"2026-12-31",{"name":263,"class":43},"Chinese Academy of Medical Sciences, Fuwai Hospital",{"id":265,"slug":266,"hasResults":11,"nctId":267,"briefTitle":268,"officialTitle":269,"acronym":270,"eligibilityCriteria":271,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":272,"targetDuration":4,"studyType":24,"phases":273,"briefSummary":274,"conditions":275,"keywords":4,"overallStatus":231,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":284,"locationsCount":4},"100618287","crystalloid-vs-colloid-for-hemodynamics-during-anesthesia-induction-in-tavr-patients-100618287","NCT07329660","Crystalloid vs Colloid for Hemodynamics During Anesthesia Induction in TAVR Patients","The Impact of Different Preload Strategies on Hemodynamics During Anesthesia Induction in TAVR Patients","CHAIN-T","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* Patients scheduled to undergo elective TAVR under general anesthesia;\n\nExclusion Criteria:\n\n* Allergy to hydroxyethyl starch, its components, and\u002For sodium lactate Ringer's solution, or a history of colloidal allergy;\n* Severe cardiac dysfunction (ejection fraction\\[EF\\] \\\u003C 35%);\n* Severe renal dysfunction (creatinine \\> 132 μg\u002FL and\u002For requiring renal replacement therapy);\n* Morbid obesity (body mass index\\[BMI\\] \\> 37.5 kg\u002Fm² or \\> 32.5 kg\u002Fm² with metabolic diseases);\n* Severe hepatic dysfunction ;\n* Severe electrolyte disturbances ;\n* Patients with preoperative intracranial hypertension requiring dehydration therapy;\n* Expected postoperative hospital stay \\\u003C 24 hours;\n* Patients scheduled for multiple surgeries during this hospitalization.",{"count":225,"type":23},[55],"The purpose of this study is to evaluate whether the administration of 5 ml\u002Fkg of colloid solution prior to anesthesia induction, compared with 5 ml\u002Fkg of lactated Ringer's solution, can reduce hemodynamic fluctuations during the induction period (defined as the first 15 minutes after induction) in patients undergoing Transcatheter Aortic Valve Replacement (TAVR).",[29,276,277],"Hemodynamic Stability","Anesthesia Induction","2026-02-25",{"date":280,"type":36},"2026-02-27",{"date":282,"type":23},"2026-02-16",{"date":261,"type":23},{"name":285,"class":43},"Air Force Military Medical University, China",{"id":287,"slug":288,"hasResults":11,"nctId":289,"briefTitle":290,"officialTitle":291,"acronym":292,"eligibilityCriteria":293,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":294,"targetDuration":4,"studyType":24,"phases":295,"briefSummary":296,"conditions":297,"keywords":299,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":312,"locationsCount":44},"100590050","clinical-feasibility-and-evaluation-study-of-point-guard-embolic-protection-device-during-tavr-guardian-100590050","NCT06962371","Clinical Feasibility and Evaluation Study of POINT-GUARD Embolic Protection Device During TAVR (GUARDIAN)","GUARDIAN Australian Feasibility Study: Safety and Feasibility","GUARDIAN","Inclusion Criteria:\n\n1. The patient is ≥18 years of age;\n2. The patient meets indications for Transcatheter Aortic Valve Replacement (TAVR);\n3. The patient is willing to comply with protocol-specified follow-up evaluations;\n4. The patient has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent, approved by the appropriate Institutional Review Board or Ethics Committee.\n\nExclusion Criteria:\n\n1. TAVR conducted via other than transfemoral access (subclavian, axillar, transapical, transaortic, carotid or transcaval).\n2. Anatomy that precludes safe delivery and retrieval of the investigational device.\n3. Current or planned treatment with any investigational drug or investigational device during the study enrollment or follow-up period.\n4. Cardiovascular surgical or interventional procedure 10 days prior or planned during the TAVR procedure or during the 30-day study follow-up.\n5. Patients with uncontrolled bleeding disorders.\n6. Patients who are pregnant, as confirmed by a positive pregnancy test.\n\nGeneral Exclusion Criteria\n\n1. TAVR conducted via other than transfemoral access (subclavian, axillar, transapical, transaortic, carotid or transcaval).\n2. Anatomy that precludes safe delivery and retrieval of the investigational device.\n3. Current or planned treatment with any investigational drug or investigational device during the study enrollment or follow-up period.\n4. Cardiovascular surgical or interventional procedure 10 days prior or planned during the TAVR procedure or during the 30-day study follow-up.\n5. Patients with uncontrolled bleeding disorders.\n\n5\\. Patients who are pregnant, as confirmed by a positive pregnancy test.\n\nMagnetic resonance imaging exclusion criteria:\n\n1. Body Mass Index (BMI) and\u002For total body weight precluding imaging in scanner.\n2. Contraindications to MRI (subjects with any implantable temporary or permanent pacemaker or defibrillator, metal implants in field of view, metallic fragments, clips, or devices in the brain or eye before TAVR procedure).\n3. High risk of complete AV block after TAVR, with the need of permanent pacemaker (e.g., subjects with pre-existing bifascicular block or complete right bundle branch block plus any degree of AV block).\n4. Existing or planned implantation of a pacemaker or defibrillator implantation within the first 3 days after TAVR.\n5. Claustrophobia precluding MRI scanning.",{"count":250,"type":23},[55],"The purpose of this study is to assess the feasibility and safety of the Transverse Medical, Inc. Point-Guard device. This feasibility study is a limited clinical investigation of the Point-Guard device. The study will be conducted to evaluate the device design concept with respect to clinical safety and device functionality.",[298,164,29],"Transcatheter Aortic Valve Implantation (TAVI)",[300,301,302,303,304,305],"CEP","Cerebral Embolic Protection","CEP Device","TAVR","TAVI","stroke","2025-04-29",{"date":308,"type":36},"2025-05-08",{"date":310,"type":36},"2025-04-07",{"date":236,"type":23},{"name":313,"class":314},"Transverse Medical, Inc.","INDUSTRY",{"id":316,"slug":317,"hasResults":11,"nctId":318,"briefTitle":319,"officialTitle":319,"acronym":320,"eligibilityCriteria":321,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":322,"targetDuration":4,"studyType":24,"phases":324,"briefSummary":326,"conditions":327,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":329,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":335,"locationsCount":44},"100555917","phase-3-short-versus-long-antiplatelet-therapy-after-tavi-100555917","NCT06518317","Short Versus Long Antiplatelet Therapy After TAVI","SOLOTAVI","Inclusion Criteria:\n\n* Age ≥ 18\n* Male or, post-menopausal -with no menses for 12 months without an alternative medical cause- or permanently sterilized -hystercetomy, bilateral salpingectomy or bilateral oophorectomy- female\n* Successful transfemoral TAVI for symptomatic aortic stenosis as defined by VARC-33\n\n  * Successful access, delivery of the device, and retrieval of the delivery system\n  * Correct positioning of a single prosthetic heart valve into the proper anatomical location\n  * Freedom from surgery or intervention related to the device (excluding permanent pacemaker) or to a major vascular or access-related, or cardiac structural complication\n* Written informed consent\n* Social security affiliated\n* French speaking\n\nExclusion Criteria:\n\n* Un-successful TAVI defined by the absence of any of the above-mentioned criteria defining successful TAVI3\n* Alternative non-femoral-approach TAVI: apical, direct trans-aortic, subclavian, axillary or carotid approaches\n* TAVI for other indications than aortic stenosis (pure aortic regurgitation)\n* Valve in valve TAVI\n* Any indication for long term antiplatelet therapy: (e.g. coronary artery disease, cerebrovascular disease, peripheral arterial disease…) at any time prior to randomization\n* Any indication for oral anticoagulation: (e.g. atrial fibrillation, deep vein thrombosis, pulmonary embolism, ventricular thrombus…) at any time prior to randomization\n* Patients on long term antiplatelet or anticoagulant therapy prior to TAVI for any other indication than TAVI\n* Any contraindication to long term antiplatelet therapy (e.g. allergy or intolerance to aspirin, major bleeding, high bleeding risk, thrombocytopenia \\\u003C 50 000, major haemostasis disorder…)\n* Women of childbearing potential: non menopaused -with no menses for 12 months without an alternative medical cause- and not permanently sterilized -hystercetomy, bilateral salpingectomy or bilateral oophorectomy-\n* Adult with protective measures (tutorship, curatorship)\n* Patients considered as vulnerable by the investigators because of medical, psychological or social conditions:\n\n  * Patients with known or discovered severe cognitive impairment\n  * Patients with treated or untreated severe psychological or psychiatric conditions\n  * Patients with uncorrected severe hearing or visual handicap\n  * Patients with addictive alcohol, drug or substance abuse\n  * Patients with protective measures (guardianship, tutorship, curatorship)\n  * Any other condition considered by the investigators as not warranting informed consent",{"count":323,"type":23},1400,[325],"PHASE3","The goal of this clinical trial is to learn if reducing the duration of treatment by aspirin to 3 months (short treatment regimen) after percutaneous aortic valve replacement is as safe and efficient as the routine lifetime treatment by aspirin (standard treatment regimen).\n\nThe main questions it aims to answer are:\n\nDoes the reduction of the duration of aspirin reduces rates of bleeding without increasing the risk of cardiovascular events.\n\nResearchers will compare a short treatment by aspirin (3 months) to a long treatment by aspirin (12 months) after percutaneous replacement of the aortic valve.\n\nParticipants will:\n\nTake aspirin for 3 months in one group or 12 months in another group Be contacted by phone or visit the clinic at 3, 4, 6, 8, 10 and 12 months after hospital discharge Keep a diary of any bleeding or cardiovascular events occurring during the study period",[29],"2025-03-24",{"date":330,"type":36},"2025-03-26",{"date":332,"type":36},"2024-11-21",{"date":334,"type":23},"2029-01",{"name":336,"class":43},"University Hospital, Caen",{"id":338,"slug":339,"hasResults":11,"nctId":340,"briefTitle":341,"officialTitle":342,"acronym":4,"eligibilityCriteria":343,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":344,"targetDuration":4,"studyType":24,"phases":345,"briefSummary":346,"conditions":347,"keywords":355,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":362,"startDateStruct":363,"completionDateStruct":365,"leadSponsor":367,"locationsCount":44},"100584966","tavr-the-impact-of-prothesis-positioning-on-valvular-and-coronary-hemodynamics-100584966","NCT06896227","TAVR: The Impact of Prothesis Positioning on Valvular and Coronary Hemodynamics","Transcatheter Aortic Valve Implantation (TAVR): The Impact of Prothesis Positioning on Valvular and Coronary Hemodynamics","Inclusion Criteria\n\n\\- Patients who have undergone transfemoral transcatheter aortic valve replacement (TAVR).\n\nExclusion Criteria\n\n* Any access route other than transfemoral.\n* Valve-in-valve procedures.\n* History of prior bioprosthetic valve implantation.\n* Presence of pacemaker, implantable cardioverter-defibrillator (ICD), or cardiac resynchronization therapy (CRT) system.\n* Diagnosis of liver cirrhosis.\n* Esophageal disorders, including but not limited to esophageal varices.\n* Thrombocytopenia or coagulation disorders.\n* Any medical or psychiatric condition (e.g., dementia, alcoholism, or substance abuse) that may impair the ability to provide informed consent or interfere with study procedures, including follow-up visits.",{"count":184,"type":23},[55],"The aim of this clinical study is to learn more about the effects of TAVR-prosthesis positioning on hemodynamics and the coronary arteries.\n\nThe main questions it aims to answer are:\n\n1. Does the cardiac magnetic resonance imaging and the echocardiography imaging provide an equivalent alternative to the computer tomography which is the state of the art in evaluating commissural alignment?\n2. What effect does the position of the valve on the annular level have, especially its symmetrical and commissural position, on valvular and aortic blood flow characteristics?\n3. What is the influence of symmetrical position and the presence of a commissural alignment on the coronary flow after transcatheter aortic valve replacement?",[29,348,349,350,351,352,353,164,354],"Transcatheter Aortic Valve Implantation","Commissural Alignment","Commissural Misalignment","Symmetry","Prothesis Positioning","Prosthesis Durability","Aortic Valve Disease",[303,304,356,351,357,358,359,360],"Commissural alignment","Prothesis positioning","cMRI","4D Flow","TEE","2025-03-19",{"date":330,"type":36},{"date":364,"type":36},"2024-10-22",{"date":366,"type":23},"2025-12-31",{"name":368,"class":43},"Heinrich-Heine University, Duesseldorf",{"id":370,"slug":371,"hasResults":11,"nctId":372,"briefTitle":373,"officialTitle":374,"acronym":4,"eligibilityCriteria":375,"healthyVolunteers":11,"sex":18,"minAge":376,"maxAge":377,"enrollmentInfo":378,"targetDuration":380,"studyType":81,"phases":4,"briefSummary":381,"conditions":382,"keywords":384,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":386,"startDateStruct":388,"completionDateStruct":390,"leadSponsor":392,"locationsCount":44},"100457358","effectavi-registry-100457358","NCT05235555","EffecTAVI Registry","Safety and Effectiveness of Transcatheter Aortic Valve Implantation - EffecTAVI Registry","Inclusion Criteria:\n\n1. Patients with symptomatic severe AS or degenerated bioprosthetic aortic valve and suitable for TAVI according to Heart Team evaluation;\n2. Ability to provide informed consent.\n\nExclusion Criteria:\n\n1. Contraindications to TAVI: e.g. evidence of intracardiac mass, thrombus or vegetation, endocarditis;\n2. Poor adherence to scheduled follow-up;\n3. Unable to understand and follow study-related instructions.","55 Years","100 Years",{"count":379,"type":23},1000,"10 Years","Aortic stenosis (AS) is the most common valvular heart disease among elderly population, with a increasing prevalence due to population ageing. In developed countries, the prevalence of severe AS among ≥75 years is approximately 3.4%. The onset of symptoms is associated with a poor prognosis. Indeed, mortality increases once symptoms appears.\n\nFor several decades, surgical aortic valve replacement (SAVR) has been the standard of care for symptomatic AS. Transcatheter aortic valve implantation (TAVI) was introduced as alternative treatment in inoperable patients in 2002. In the last two decades TAVI has led to a paradigm shift in the treatment of severe AS, representing a less invasive alternative to surgery. TAVI has shown to be non-inferior or superior to SAVR in several large-scale randomized clinical trials (RCTs) across the full spectrum of surgical risks. The newly available evidence has led to an expansion of guideline recommendations for TAVI. Furthermore, newer generations of transcatheter heart valve (THV) design, better patient selection, and technical enhancements have driven improvement in safety and reduction of procedural complications over time.\n\nThis observational study aim to prospectively evaluate the safety and efficacy of the procedure and clinical outcomes in patients undergoing TAVI.",[383,29,304],"Aortic Stenosis",[383,29,304],"2024-02-22",{"date":387,"type":36},"2024-02-23",{"date":389,"type":36},"2015-09-01",{"date":391,"type":23},"2030-01-01",{"name":393,"class":43},"Federico II University",{"id":395,"slug":396,"hasResults":11,"nctId":397,"briefTitle":398,"officialTitle":399,"acronym":400,"eligibilityCriteria":401,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":402,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":403,"conditions":404,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":407,"startDateStruct":409,"completionDateStruct":411,"leadSponsor":413,"locationsCount":44},"100397365","smart-watch-facilitated-early-discharge-in-patients-undergoing-transcatheter-aortic-valve-replacement-100397365","NCT04454177","SMART Watch Facilitated Early Discharge in Patients Undergoing Transcatheter Aortic Valve Replacement","SMART TAVR: SMART Watch Facilitated Early Discharge in Patients Undergoing Transcatheter Aortic Valve Replacement","SMART TAVR","Inclusion Criteria:\n\n* At least 18 years old;\n* Be willing and able to provide informed consent to participate in the study;\n* Not share HUAWEI Watch, HUAWEI phone with anyone else;\n* Patient has severe aortic stenosis with echocardiographically derived criteria: mean gradient \\> 40mmHg or maximum velocity greater than 4.0 m\u002Fs or an initial aortic valve area of \\\u003C 1.0 cm2;\n* Patient who undergoing elective transfemoral transcatheter aortic valve replacement.\n\nExclusion Criteria:\n\n* Severe complications of TAVR, such as death, and conversion to SAVR;\n* Life expectancy is less than 12 months due to non-heart disease (such as cancer, chronic liver disease, chronic kidney disease, or chronic end-stage lung disease, etc.);\n* Severe dementia (cannot sign research informed consent, cannot take care of themselves or complete the study visit);\n* The investigator believes that the patient is not suitable to participate in the study or complete the follow-up prescribed by the protocol from other medical, social and psychological aspects;\n* The patient is currently participating in another randomized study.",{"count":184,"type":23},"The purpose of this study is to observe conduction disturbance, daily activity level, heart rates, oxygen saturation in patients who underwent Transcatheter Aortic Valve Replacement (TAVR) and to evaluate the utility of the HUAWEI Watch (HUAWEI Technologies Co., Ltd., Shenzhen, China) for the potential early warning sign of changes in multiple biometric parameters including heart rate, rhythm, oxygen saturation, activity, and sleep in patients following TAVR. This will be evaluated in the context of a recently implemented early discharge protocol.",[383,405,29],"Valvular Heart Disease","2020-10-25",{"date":408,"type":36},"2020-10-27",{"date":410,"type":36},"2020-07-15",{"date":412,"type":23},"2031-07-01",{"name":414,"class":43},"Second Affiliated Hospital, School of Medicine, Zhejiang University"]